Abbott Laboratories vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Abbott Laboratories and Johnson & Johnson are compared as healthcare investments for 2026. Abbott trades at lower valuations with expected 13% sales growth but faces litigation risks and slower growth in key products like FreeStyle Libre. Johnson & Johnson offers superior profitability and a robust pharmaceutical pipeline with 28 billion-dollar products, though it faces talc settlement costs and biosimilar competition. Abbott is recommended as the better buy due to stronger expected sales growth and lower valuation metrics.